Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus NADOLOL AND BENDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus NADOLOL AND BENDROFLUMETHIAZIDE.
BETAPACE vs NADOLOL AND BENDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Nadolol is a nonselective beta-adrenergic receptor antagonist that blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water and reducing plasma volume.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Nadolol 40–80 mg orally once daily; bendroflumethiazide 2.5–5 mg orally once daily. Dose titration based on blood pressure response.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Nadolol: 14–24 h (mean 20 h); allows once-daily dosing. Bendroflumethiazide: 3–4 h (terminal); clinical duration longer due to prolonged action on distal tubule.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Nadolol: ~70% renal unchanged, ≤5% fecal. Bendroflumethiazide: ~30% renal unchanged, ~70% renal as metabolites; minimal biliary.
Category C
Category C
Beta-Blocker
Beta-Blocker